Cargando…
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
PURPOSE: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer enrolled in the BROCADE3 trial who received crossover veliparib monotherapy after disease progression on pl...
Autores principales: | Puhalla, Shannon L., Diéras, Véronique, Arun, Banu K., Kaufman, Bella, Wildiers, Hans, Han, Hyo S., Ayoub, Jean-Pierre, Stearns, Vered, Yuan, Yuan, Helsten, Teresa, Riley-Gillis, Bridget, Murphy, Erin, Kundu, Madan G., Wu, Meijing, Maag, David, Ratajczak, Christine K., Ramathal, Cyril Y., Friedlander, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401555/ https://www.ncbi.nlm.nih.gov/pubmed/34131001 http://dx.doi.org/10.1158/1078-0432.CCR-21-0748 |
Ejemplares similares
-
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial
por: Ayoub, Jean-Pierre, et al.
Publicado: (2021) -
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017) -
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022) -
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial
por: Aghajanian, Carol, et al.
Publicado: (2022) -
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
por: Peretti, U., et al.
Publicado: (2021)